Role of pharmacodiagnostic of CYP2C9 variants in the optimization of warfarin therapy in Malaysia: A 6-month follow-up study
- 1 June 2008
- journal article
- research article
- Published by Taylor & Francis in Xenobiotica
- Vol. 38 (6) , 641-651
Abstract
1. A retrospective study was conducted to explore the importance of CYP2C9 genotyping for the initiation and maintenance therapy of warfarin in clinical practice. A total of 191 patients on warfarin therapy in a local hospital were recruited after written informed consent. Their medical records were reviewed and no intervention of warfarin dose was performed. 2. A total of 5 ml of blood were taken from each subject for DNA extraction and identification of *1, *2, *3 and *4 CYP2C9 alleles, using a nested-allele-specific-multiplex-polymerase chain reaction (PCR). Half the patients were Malays and the remaining were Chinese. 3. Two genotypes were detected; 93.2% had CYP2C9*1/*1 and 6.8% were CYP2C9*1/*3. Warfarin doses were higher in patients with CYP2C9*1/*1. Patients with the *1/*3 genotype experienced a higher rate of serious and life-threatening bleeding; 15.4 versus 6.2 per 100 patients per 6 months. 4. The observation clearly highlights the inadequacy of the current dosing regimens and the need to move toward a more individualized approach to warfarin therapy. Prospective clinical studies are now being conducted to assess dosing algorithms that incorporate the contribution of the genotype to allow the individualization of warfarin dose.Keywords
This publication has 17 references indexed in Scilit:
- Malaysian Indians are genetically similar to Caucasians: CYP2C9 polymorphismJournal of Clinical Pharmacy and Therapeutics, 2006
- The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimenBlood, 2005
- Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivityBlood, 2005
- A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarinBlood, 2005
- Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2Nature, 2004
- A Multicomponent Intervention To Prevent Major Bleeding Complications in Older Patients Receiving WarfarinAnnals of Internal Medicine, 2000
- Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complicationsThe Lancet, 1999
- Bleeding During Antithrombotic Therapy in Patients With Atrial FibrillationArchives of internal medicine (1960), 1996
- Optimal Oral Anticoagulant Therapy in Patients with Mechanical Heart ValvesNew England Journal of Medicine, 1995
- Risk Factors for Complications of Chronic Anticoagulation: A Multicenter StudyAnnals of Internal Medicine, 1993